- People
- Offices
- Capabilities
back- Capabilities
- Corporate, Finance and Investments
- back
- Corporate, Finance and Investments
- Overview
- Activist Defense
- Capital Markets
- Construction and Procurement
- Corporate Governance
- Emerging Companies and Venture Capital
- Employee Benefits and Executive Compensation
- Energy and Infrastructure Projects
- Financial Restructuring
- Global Human Capital and Compliance
- Investment Funds and Asset Management
- Leveraged Finance
- Mergers and Acquisitions
- Middle East and Islamic Finance and Investment
- Private Credit & Special Situations Investing
- Private Equity
- Public Companies
- Real Estate
- Securitization
- Tax
- Technology Transactions
- Government Matters
- back
- Government Matters
- Overview
- Antitrust
- Data, Privacy and Security
- Environmental, Health and Safety
- FDA and Life Sciences
- Government Advocacy and Public Policy
- Government Contracts
- Healthcare
- International Trade
- National Security and Corporate Espionage
- Securities Enforcement and Regulation
- Special Matters and Government Investigations
- Trial and Global Disputes
- back
- Trial and Global Disputes
- Overview
- Appellate, Constitutional and Administrative Law
- Bankruptcy and Insolvency Litigation
- Class Action Defense
- Commercial Litigation
- Construction and Engineering Disputes
- Corporate and Securities Litigation
- E-Discovery
- Intellectual Property
- International Arbitration and Litigation
- Labor and Employment
- Product Liability
- Professional Liability
- Toxic & Environmental Torts
- Industries / Issues
- back
- Industries / Issues
- Automotive, Transportation and Mobility
- Energy
- Financial Services
- Food and Beverage
- Franchise and Hospitality
- Higher Education
- Life Sciences and Healthcare
- Technology
- #MeToo
- Buy American
- COVID-19 Vaccine Rollout
- Coronavirus
- Crisis Practice
- Environmental Agenda
- Focus on Women's Health
- Special Purpose Acquisition Companies (SPACs)
- The New Administration: Enforcement and Legislative Impact
- Careers
- News & Insights
- About
- Languages
Juliet M. McBride
Insights 116 results
COVID-19 Vaccine Updates
April 30, 2021
Moderna to Make Additional Investments and Produce 3 Billion Vaccine Doses in 2022
COVID-19 Vaccine Updates
April 30, 2021
CDC Says Pfizer and Moderna COVID-19 Vaccines are 94% Effective Against Hospitalization in Older Adults
COVID-19 Vaccine Updates
April 30, 2021
CDC Reveals New Guidelines for Fully Vaccinated Individuals
COVID-19 Vaccine Updates
April 26, 2021
White House COVID-19 Response Team Announces Successful Administration of 200 Million Shots in 100 Days
COVID-19 Vaccine Updates
April 26, 2021
CDC and FDA Lift Recommended Pause on Johnson & Johnson COVID-19 Vaccine
COVID-19 Vaccine Updates
April 22, 2021
CDC Publishes Two Reports on Post-Vaccination COVID-19 Outbreaks in Skilled Nursing Facilities
COVID-19 Vaccine Updates
April 22, 2021
HHS Launches “We Can Do This: Live” Initiative to Increase COVID-19 Vaccine Confidence
COVID-19 Vaccine Updates
April 21, 2021
EU Exercises Option to Acquire an Additional 100 Million Vaccine Doses from Pfizer and BioNTech
COVID-19 Vaccine Updates
April 21, 2021
World Bank Provides $2 Billion in Approved Financing for COVID-19 Vaccine Rollout in Developing Countries
COVID-19 Vaccine Updates
April 21, 2021
IRS Announces Employer Tax Credit for COVID-19 Vaccination Paid Time Off
COVID-19 Vaccine Updates
April 19, 2021
White House Announces 50 Percent of US Adults Have Received At Least One Dose of a COVID-19 Vaccine
COVID-19 Vaccine Updates
April 16, 2021
CDC and FDA Release Joint Statement on Johnson & Johnson COVID-19 Vaccine